[go: up one dir, main page]

WO2018213813A3 - Psychotropic agents and uses thereof - Google Patents

Psychotropic agents and uses thereof Download PDF

Info

Publication number
WO2018213813A3
WO2018213813A3 PCT/US2018/033552 US2018033552W WO2018213813A3 WO 2018213813 A3 WO2018213813 A3 WO 2018213813A3 US 2018033552 W US2018033552 W US 2018033552W WO 2018213813 A3 WO2018213813 A3 WO 2018213813A3
Authority
WO
WIPO (PCT)
Prior art keywords
amisulpride
enantiomer
individually
pharmaceutical composition
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/033552
Other languages
French (fr)
Other versions
WO2018213813A2 (en
WO2018213813A8 (en
Inventor
Andrew R. VAINO
Vincent T. GRATTAN
Zachary PRENSKY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LB Pharmaceuticals Inc
Original Assignee
LB Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LB Pharmaceuticals Inc filed Critical LB Pharmaceuticals Inc
Priority to CN201880048781.8A priority Critical patent/CN110944630A/en
Priority to EP18801735.4A priority patent/EP3625212A4/en
Publication of WO2018213813A2 publication Critical patent/WO2018213813A2/en
Priority to US16/579,545 priority patent/US11377421B2/en
Publication of WO2018213813A8 publication Critical patent/WO2018213813A8/en
Anticipated expiration legal-status Critical
Publication of WO2018213813A3 publication Critical patent/WO2018213813A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The R enantiomer of amisulpride and amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for antagonizing serotonin (e.g., 5-HT2a, 5-HT7) receptor in a subject, either individually or in combination with other CNS active agents. The R enantiomer of amisulpride and amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more conditions responsive to modulation of serotonin (e.g., 5-HT2a, 5-HT7) receptor in a subject, either individually or in combination with other CNS active agents. The R enantiomer of amisulpride and amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more disorders associated with an abnormality in levels of serotonin in the brain, either individually or in combination with other CNS active agents.
PCT/US2018/033552 2016-11-28 2018-05-18 Psychotropic agents and uses thereof Ceased WO2018213813A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201880048781.8A CN110944630A (en) 2017-05-18 2018-05-18 Psychotropic drugs and their uses
EP18801735.4A EP3625212A4 (en) 2017-05-18 2018-05-18 PSYCHOTROPIC AGENTS AND USES THEREOF
US16/579,545 US11377421B2 (en) 2016-11-28 2019-09-23 Psychotropic agents and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762508263P 2017-05-18 2017-05-18
US62/508,263 2017-05-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US16/383,933 Continuation-In-Part US20200079734A1 (en) 2016-11-28 2019-04-15 Psychotropic agents and uses thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/383,933 Continuation-In-Part US20200079734A1 (en) 2016-11-28 2019-04-15 Psychotropic agents and uses thereof
US16/579,545 Continuation-In-Part US11377421B2 (en) 2016-11-28 2019-09-23 Psychotropic agents and uses thereof

Publications (3)

Publication Number Publication Date
WO2018213813A2 WO2018213813A2 (en) 2018-11-22
WO2018213813A8 WO2018213813A8 (en) 2019-11-07
WO2018213813A3 true WO2018213813A3 (en) 2019-12-12

Family

ID=64274762

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/033552 Ceased WO2018213813A2 (en) 2016-11-28 2018-05-18 Psychotropic agents and uses thereof

Country Status (3)

Country Link
EP (1) EP3625212A4 (en)
CN (1) CN110944630A (en)
WO (1) WO2018213813A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11377421B2 (en) 2016-11-28 2022-07-05 Lb Pharmaceuticals Inc. Psychotropic agents and uses thereof
KR102274338B1 (en) 2016-11-28 2021-07-06 엘비 파마슈티칼스 인크. Psychotropic agents and their uses
WO2022245991A1 (en) * 2021-05-18 2022-11-24 Lb Pharmaceuticals Inc. Psychotropic agents and uses thereof
CN117074579B (en) * 2023-10-16 2023-12-22 江苏东科康德药业有限公司 Analysis method of related substances of amisulpride oral solution

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4210660A (en) * 1978-12-20 1980-07-01 Yamanouchi Pharmaceutical Co., Ltd. Benzamide derivatives
US6069165A (en) * 1996-09-18 2000-05-30 Synthelabo Pharmaceutical compositions containing amisulpride and their therapeutic applications

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050203130A1 (en) * 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20100105755A1 (en) * 2008-09-12 2010-04-29 Auspex Pharmaceuticals, Inc. Substituted benzamide modulators of dopamine receptor
KR102274338B1 (en) * 2016-11-28 2021-07-06 엘비 파마슈티칼스 인크. Psychotropic agents and their uses
KR20200110648A (en) * 2017-12-05 2020-09-24 선오비온 파마슈티컬스 인코포레이티드 Non-racemic mixtures and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4210660A (en) * 1978-12-20 1980-07-01 Yamanouchi Pharmaceutical Co., Ltd. Benzamide derivatives
US6069165A (en) * 1996-09-18 2000-05-30 Synthelabo Pharmaceutical compositions containing amisulpride and their therapeutic applications

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DONAHUE J TIMOTHY: "CHARACTERIZATION OF THE DISCRIMINATIVE STIMULUS PROPERTIES OF THE ATYPICAL ANTIPSYCHOTIC AMISULPRIDE IN C57BL/6 MICE", 12 February 2014 (2014-02-12), pages 1 - 141, XP055603263, Retrieved from the Internet <URL:https://scholarscompass.vcu.edu/cgi/viewcontent.cgi?article=4609&context=etd> *

Also Published As

Publication number Publication date
WO2018213813A2 (en) 2018-11-22
CN110944630A (en) 2020-03-31
EP3625212A2 (en) 2020-03-25
WO2018213813A8 (en) 2019-11-07
EP3625212A4 (en) 2021-03-31

Similar Documents

Publication Publication Date Title
MY205036A (en) Psychotropic agents and uses thereof
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
PH12022550359A1 (en) Nonpeptide somatostatin type 5 receptor agonists and uses thereof
PH12019500208A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500202A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
JOP20190281A1 (en) N2,n4-diphenylpyrimidin-2,4-diamine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer
PH12019500207A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
WO2018213813A8 (en) Psychotropic agents and uses thereof
PH12019500206A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2021015500A (en) Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators.
MX2021015503A (en) Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators.
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
MX2018000352A (en) Substituted 4-azaindoles and their use as glun2b receptor modulators.
CR20210580A (en) Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators
MX383292B (en) SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND THEIR USE.
EP4603148A3 (en) Deuterium-enriched pirfenidone and methods of use thereof
BR112021014566A2 (en) gpr35 modulators
MX2021014987A (en) Modified release pharmaceutical compositions of huperzine and methods of using the same.
MX2022011310A (en) Azabicyclo and diazepine derivatives for treating ocular disorders.
PH12017501736B1 (en) Indole derivatives
WO2020065090A3 (en) 5-ht7 antagonist for the treatment of dementia-associated tauopathies
WO2019244014A3 (en) New use of inhibitors of monoamine oxidase type b
AU2018258348A1 (en) Novel compositions for preventing and/or treating degenerative disorders of the central nervous system and/or lysosomal storage disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18801735

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018801735

Country of ref document: EP

Effective date: 20191218